Human Polyclonal Antibody to Treat Unvaccinated Non-Hospitalized Adult Patients

Community NewsNews
26

Translate to Spanish or other 102 languages!

Enrollment in this study is voluntary and the patients will not be charged for this treatment and/or the follow-up. Image for illustration purposes.
Enrollment in this study is voluntary and the patients will not be charged for this treatment and/or the follow-up. Image for illustration purposes.

Mega Doctor News

- Advertisement -

EDINBURG, Texas – DHR Health is involved in a new and innovative study to use human polyclonal antibody to treat non-hospitalized patients who are >18 years of age with mild-moderate COVID-19. Safety of this human polyclonal antibody (SAB-185) has already been established. This would be the first such study in which human polyclonal antibodies will be used to treat patients with COVID-19.

“We are embarking on a new study that is FDA-approved and NIH-funded to infuse human polyclonal antibodies in non-hospitalized unvaccinated high-risk individuals who are COVID-19 positive” said Sohail Rao, MD, MA, DPhil, President & CEO, DHR Health Institute for Research & Development. “The human polyclonal antibody has been shown to neutralize both wild-type and various variants of SARS-CoV-2 virus including Delta. the primary objective of this study is to prevent hospitalization of the patients with COVID-19.”

The study entails a single treatment with either REGEN-COV monoclonal antibody or SAB-185 human polyclonal antibody which is infused intravenously. Enrollment in this study is voluntary and the patients will not be charged for this treatment and/or the follow-up. To learn more about who would qualify for this treatment, please visit this weblink: https://youtu.be/u8lubUkucNY or call COVID-19 treatment hotline (956) 362-2393 (9:00 a.m. – 5:00 p.m.; M-F) or (956) 342-2383 for more information.

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Virtual lung cancer screening is just as effective as in-person screening
Next article
Local Hospital Held 3rd Annual Spooktacular Stroke Awareness 5K

More Articles

Study Reveals Link Between Parent and Child Weight Is Mostly Genetic

The link between parents’ body mass index (BMI) and their children’s BMI in childhood is driven largely by genetic inheritance, rather than by any direct biological effects of parental weight during pregnancy, a new study suggests.

DHR Health Continues to Lead the Way in Treatment of Alzheimer’s Disease for the RGV

Two years after DHR Health announced it was the first hospital south of San Antonio to successfully administer Leqembi, an FDA-approved intravenous treatment for early Alzheimer’s disease, DHR Health continues to expand access to advanced Alzheimer’s care for patients in the Rio Grande Valley being now the only facility doing amyloid PET Scans, a diagnostic test to accurately diagnose Alzheimer’s disease. DHR Health also offers Kisunla, another FDA-approved intravenous treatment for early symptomatic Alzheimer’s disease.

The Genetic Armor Defeating Colorectal Cancer

A team of scientists from the Barbara Ann Karmanos Cancer Institute, Wayne State University, and institutions across the U.S., have published a landmark paper on the role of TGFBR1*6A, a naturally occurring genetic mutation in the TGFBR1 gene found in approximately 14 percent of the general population. Image for illustration purposes

Why CKM Syndrome Requires a Coordinated Care Point Person

When the term “cardiovascular-kidney-metabolic syndrome” was created in 2023 to define how heart disease, kidney disease, obesity and diabetes are connected, one goal was to help health professionals understand the benefits of working together.
- Advertisement -